National News

AtriCure to Announce First Quarter 2014 Financial Results

04.04.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 4, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the first quarter of 2014 on Thursday, April 24, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 24, 2014 to discuss its first quarter 2014 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure’s corporate website at www.atricure.com. You may also access this call through an operator by calling (866) 271-6130 for domestic callers...

Read More

AtriCure to Present at the Cowen and Company 34th Annual Health Care Conference

02.28.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 28, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place on Wednesday, March 5, 2014. Management is scheduled to present at 9:20 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation at www.atricure.com. About AtriCure, Inc. AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) s...

Read More

AtriCure Reports Fourth Quarter and Full Year 2013 Financial Results

02.27.2014
2013 revenue of $81.9 million – up 16.6% 2013 U.S. sales of $62.3 million – up 18.4% Fourth quarter revenue of $21.9 million – up 19.2% WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 27, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (“Afib”) medical device provider, today announced fourth quarter and full year 2013 financial results. “We are pleased with our team’s performance in 2013 and momentum as we move into 2014. Our commitment to training and education, clinical trial support and innovation, coupled with our strategic acquisition of Estech, pos...

Read More

AtriCure Prices Public Offering of Common Stock

02.13.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 13, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced the pricing of its previously announced underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $19.25 per share. AtriCure is offering 3,023,025 shares and selling stockholders are offering 1,226,975 shares of common stock. In connection with the offering, AtriCure has also granted the underwriter a 30-day option to purchase up to an additional 637,500 shares of common stock to cover over-allotments, if any. Net proceeds from t...

Read More

AtriCure Announces Commencement of Public Offering of Common Stock

02.12.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 12, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that AtriCure and certain selling stockholders intend to offer shares of AtriCure common stock in a public offering. AtriCure also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital. AtriCure will not receive any proceeds from the sale of common stock by the selling stockholders. ...

Read More

AtriCure to Announce Fourth Quarter and Full Year 2013 Financial Results

02.04.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 4, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the fourth quarter and full year 2013 on Thursday, February 27, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, February 27, 2014 to discuss its fourth quarter and full year 2013 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure’s corporate website at www.atricure.com. Pre-registration is available and recommended for this call at ...

Read More

AtriCure to Present at the Leerink Swann 2014 Global Healthcare Conference

01.20.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 20, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced that it will present at the Leerink Swann 2014 Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Wednesday, February 12, 2014. Management is scheduled to present at 11:30 a.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation at www.atricure.com. About AtriCure, Inc. AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solu...

Read More

AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2013 and Issues 2014 Guidance

01.09.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 9, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, today announced preliminary financial results for fourth quarter and full year 2013 and issued 2014 financial guidance. Preliminary revenue for the fourth quarter of 2013 is expected to be approximately $21.9 million, reflecting growth of approximately 19% over the fourth quarter of 2012. Based on this preliminary estimate, revenue from U.S. customers is expected to be $16.4 million, reflecting growth of 20%, and revenue from international customers is expected to be $5.5 million, refle...

Read More

AtriCure Completes Acquisition of Estech

01.02.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 2, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced the completion of the previously announced acquisition of Endoscopic Technologies, Inc. d/b/a Estech (“Estech”). Estech develops and markets a portfolio of innovative surgical ablation devices that enable physicians to perform a variety of traditional and minimally invasive procedures using Estech’s proprietary temperature controlled RF energy. “We are pleased to complete the acquisition of Estech, and we welcome the team to AtriCure. This transaction provides substantia...

Read More

AtriCure Announces Definitive Agreement to Acquire Estech

12.19.2013
WEST CHESTER, Ohio--(BUSINESS WIRE)--Dec. 19, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation (Afib) medical device provider, and Endoscopic Technologies, Inc. d/b/a Estech (“Estech”), today announced that they have entered into a definitive merger agreement under which AtriCure has agreed to acquire Estech for a cash-free, debt-free up-front payment of approximately 2.1 million shares or $34 million of AtriCure common stock and up to $26 million in additional consideration based on the achievement of certain revenue-based milestones. The transaction is subject to customary closing conditions and is expected t...

Read More

AtriCure Receives FDA Approval for Investigational Study to Evaluate Stroke Prevention in Atrial Fibrillation

11.19.2013
AtriClip™ Left Atrial Appendage Exclusion System to be Evaluated as Alternative to Anti-Coagulation Therapy WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 19, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading developer of solutions to treat atrial fibrillation (Afib), today announced the Food and Drug Administration’s (FDA) approval to begin enrollment in a clinical study of AtriCure’s AtriClip® Left Atrial Appendage Exclusion System. The study will evaluate the use of the AtriClip device to prevent stroke in patients with Afib. The feasibility study will enroll Afib patients at seven medical centers across the...

Read More

AtriCure Announces Upcoming Investor Conference Schedule

10.31.2013
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced that it will be participating in the following upcoming investor conferences: The 2013 Canaccord Genuity Medical Technology & Diagnostics Forum at the Westin Grand Central Hotel in New York on November 14, 2013. The Piper Jaffray 2013 Annual Health Care Conference at the New York Palace Hotel on December 4, 2013. About AtriCure, Inc. AtriCure, Inc. is a leading atrial fibrillation solutions partner, providin...

Read More

AtriCure Reports Third Quarter 2013 Financial Results

10.29.2013
Revenue of $20.1 million – up 24.8%; 24.0% constant currency U.S. sales of $15.8 million – up 28.1% International sales of $4.3 million – up 14.2%; 10.8% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 29, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced financial results for the third quarter of 2013. “We are pleased with our performance in the third quarter. Our results reflect our third consecutive quarter of double digit year over year revenue growth, driven by overall strength and our U.S. business ...

Read More

AtriCure to Announce Third Quarter 2013 Financial Results

10.07.2013
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 7, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation solutions partner providing innovative products, professional education and support for clinical science to reduce the economic and social burden of atrial fibrillation, will release its financial results for the third quarter of 2013 on Tuesday, October 29, 2013. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, October 29, 2013 to discuss its third quarter 2013 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCur...

Read More

Health Risks of Atrial Fibrillation Raised During Awareness Month

09.19.2013
AtriCure Seeks to Improve Lives by Encouraging Education and Treatment for People with Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 19, 2013-- September is Atrial Fibrillation (Afib) Awareness Month and AtriCure, Inc. (Nasdaq: ATRC) encourages those who are affected to participate in “ACT Against Afib,” a new campaign focused on raising awareness of the risks of Afib and the various treatment options available. AtriCure is a leading developer of medical devices used in the treatment of Afib and offers the only FDA-approved device for the surgical treatment of Afib. “ACT” is an acronym used to communicate the ...

Read More

AtriCure Announces Commitment to Improve Lives of 250,000 Atrial Fibrillation Patients

09.18.2013
Investment in Clinical Studies, Education to Advance New Technology Brings Hope to Patients Suffering from Afib WEST CHESTER, Ohio--(BUSINESS WIRE)--Sep. 18, 2013-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (Afib) solutions partner, has announced a significant multi-year strategic investment in clinical trial and educational initiatives aimed at reducing the global Afib epidemic. The announcement coincides with Atrial Fibrillation Awareness Month, which was created to bring attention to this growing public health issue. Afib is associated with significant morbidity and mortality from stroke an...

Read More

International News

In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe

10.01.2013
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in this important initiative. This initial course will be led by surgeons recognized as experts in the field of surgical treatment for Afib. They include: James L. Co...

Read More

Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic Surgery

06.18.2013
Patients show three-year freedom from atrial fibrillation, anti-arrhythmic drugs PRAGUE--(BUSINESS WIRE)--Jun. 18, 2013-- A leading German cardiovascular heart center reported promising mid-term results for the surgical treatment of persistent atrial fibrillation (Afib) during last week’s International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) meeting being held in Prague, Czech Republic. At three-year follow-up, 80 percent of persistent Afib patients were free from Afib and off anti-arrhythmic medications using AtriCure’s Bipolar RF Ablation System. These results compare favorably with a more comm...

Read More